Levels of neurofilament light chain, a marker of nerve cell degeneration, are increased in children with juvenile-onset Huntington’s disease…
Articles by Marisa Wexler, MS
Most young people at risk of developing Huntington’s disease are not given information about the disorder at the time…
The U.S. Food and Drug Administration (FDA) has designated valbenazine an orphan drug as a potential treatment to control the…
The experimental therapy pepinemab can aid cognition in people with early Huntington’s disease who showed signs of cognitive impairment when…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
Treatment with oral valbenazine, a dopamine-modulating medicine, significantly eased the jerky, involuntary movements of chorea after as little as two…
Mutations in the HTT gene, which cause Huntington’s disease, lead to abnormalities in development as early as two weeks after…
Sage Therapeutics is recruiting participants for a clinical trial to test the effects of its experimental therapy SAGE-718 on…
People with Huntington’s disease who have a greater sense of purpose and meaning are more likely to find contentment…
Certain people with Huntington’s disease — specifically, younger adults with milder disease — may have benefited from treatment with…